恩替卡韦联合干扰素序贯治疗慢性乙型肝炎的疗效及安全性分析  

Analysis of the efficacy and security of entecavir combined with interferon sequential therapy in the treatment of chronic hepatitis B

作　　者：崔敬荣[1] 郑翠玲[1] 刘爱清 

机构地区：[1]滨州市人民医院感染一科,山东省滨州256610 [2]滨州市滨城区区直机关医院

出　　处：《中国基层医药》2013年第17期2616-2618,共3页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的 探讨恩替卡韦和干扰素序贯联合治疗慢性乙型肝炎的疗效及安全性.方法 选取慢性乙型肝炎患者108例,按数字表法随机分为序贯联合组、恩替卡韦组和干扰素组三组,每组36例.观察不同治疗方法的疗效及安全性.结果 序贯联合组HBV DNA阴转率和丙氨酸氨基转移酶复常率分别为77.78％、91.67％,均明显高于恩替卡韦组和干扰素组（Х^2=14.40、22.12、20.07、18.47,均P＜0.05）.序贯联合组总有效率为91.67％,明显高于恩替卡韦组的55.55％和干扰素组的66.67％（Х^2=12.09、6.82,均P＜0.05）.恩替卡韦和干扰素序贯联合治疗安全性良好.结论 恩替卡韦和干扰素序贯联合治疗慢性乙型肝炎的临床疗效显著,值得在临床中推广应用.Objective To discuss the efficacy and security of entecavir and interferon sequential combination therapy on chronic hepatitis B.Methods 108 patients with chronic hepatitis B were randomly divided into the sequential combination therapy group,the entecavir group and the interferon group.Each group had 36 cases.The efficacy and security of different therapy were observed.Results The HBV DNA negative rate of the sequential combination therapy group was 77.78%,and the ALT normalization rate was 91.67%,which were both higher than those of the entecavir group and the interferon group（Х^2 =14.40,22.12,20.07,18.47,all P 〈 0.05）.The total effective rate of the sequential combination therapy group was 91.67%,which was obviously higher than that of entecavir group and the interferon group（Х^2 =12.09,6.82,all P 〈 0.05）.The entecavir and interferon sequential combination therapy had a good security.Conclusion Entecavir combined with interferon sequential therapy in the treatment of chronic hepatitis B had a significant clinical efficacy and deserved promotion.

关 键 词：恩替卡韦 干扰素 药物疗法 联合 肝炎 乙型 慢性 

分 类 号：R512.62[医药卫生—内科学]